Terms: = Leukemia AND CCND3, P30281, 896, ENSG00000112576
90 results:
1. BRD4 PROTAC degrader MZ1 exhibits anti-B-cell acute lymphoblastic leukemia effects via targeting ccnd3.
Ma L; Wang J; Yang Y; Lu J; Ling J; Chu X; Zhang Z; Tao Y; Li X; Tian Y; Li Z; Zhang Y; Sang X; Lu L; Wan X; Zhang K; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Zhou X; Hu Y; Hu S
Hematology; 2023 Dec; 28(1):2247253. PubMed ID: 37594294
[TBL] [Abstract] [Full Text] [Related]
2. Circ_0001602 aggravates the progression of acute myeloid leukemia by regulating the miR-192-5p/ZBTB20 axis.
Wu W; Deng J; Chen C; Ma X; Yu L; Chen L
Hematology; 2023 Dec; 28(1):2240133. PubMed ID: 37585722
[TBL] [Abstract] [Full Text] [Related]
3. Value of the FDP/FIB ratio in predicting early severe bleeding events in patients with newly diagnosed acute promyelocytic leukemia.
Li S; Gao Y; Li F; Zheng Y; Su Y
Ann Hematol; 2023 Apr; 102(4):787-794. PubMed ID: 36750485
[TBL] [Abstract] [Full Text] [Related]
4. [Clinical features and prognosis of eight patients with splenic diffuse red pulp small B-cell lymphoma].
Zhang XL; Luo J; Zhang JJ; Chen L; Shen Y; Yi HM; Fan LQ; Mi JQ
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1028-1033. PubMed ID: 36709109
[No Abstract] [Full Text] [Related]
5. Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome.
Parry EM; Leshchiner I; Guièze R; Johnson C; Tausch E; Parikh SA; Lemvigh C; Broséus J; Hergalant S; Messer C; Utro F; Levovitz C; Rhrissorrakrai K; Li L; Rosebrock D; Yin S; Deng S; Slowik K; Jacobs R; Huang T; Li S; Fell G; Redd R; Lin Z; Knisbacher BA; Livitz D; Schneider C; Ruthen N; Elagina L; Taylor-Weiner A; Persaud B; Martinez A; Fernandes SM; Purroy N; Anandappa AJ; Ma J; Hess J; Rassenti LZ; Kipps TJ; Jain N; Wierda W; Cymbalista F; Feugier P; Kay NE; Livak KJ; Danysh BP; Stewart C; Neuberg D; Davids MS; Brown JR; Parida L; Stilgenbauer S; Getz G; Wu CJ
Nat Med; 2023 Jan; 29(1):158-169. PubMed ID: 36624313
[TBL] [Abstract] [Full Text] [Related]
6. NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition.
Carrillo-Tornel S; Chen-Liang TH; Zurdo M; Puiggros A; Gómez-Llonín A; García-Malo MD; Cuenca-Zamora EJ; Ortuño FJ; López AMH; Espinet B; Jerez A
Br J Haematol; 2023 May; 201(3):470-479. PubMed ID: 36573331
[TBL] [Abstract] [Full Text] [Related]
7. [Effects of Thiomersal on Apoptosis and Autophagy of leukemia Cell Lines].
Wang Y; Yao H; Li ZL; Yang K; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1655-1660. PubMed ID: 36476885
[TBL] [Abstract] [Full Text] [Related]
8. Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.
Rutella S; Vadakekolathu J; Mazziotta F; Reeder S; Yau TO; Mukhopadhyay R; Dickins B; Altmann H; Kramer M; Knaus HA; Blazar BR; Radojcic V; Zeidner JF; Arruda A; Wang B; Abbas HA; Minden MD; Tasian SK; Bornhäuser M; Gojo I; Luznik L
J Clin Invest; 2022 Nov; 132(21):. PubMed ID: 36099049
[TBL] [Abstract] [Full Text] [Related]
9. Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.
Burkhardt B; Michgehl U; Rohde J; Erdmann T; Berning P; Reutter K; Rohde M; Borkhardt A; Burmeister T; Dave S; Tzankov A; Dugas M; Sandmann S; Fend F; Finger J; Mueller S; Gökbuget N; Haferlach T; Kern W; Hartmann W; Klapper W; Oschlies I; Richter J; Kontny U; Lutz M; Maecker-Kolhoff B; Ott G; Rosenwald A; Siebert R; von Stackelberg A; Strahm B; Woessmann W; Zimmermann M; Zapukhlyak M; Grau M; Lenz G
Nat Commun; 2022 Jul; 13(1):3881. PubMed ID: 35794096
[TBL] [Abstract] [Full Text] [Related]
10. [Analysis the influence factors of treatment free remission outcome with chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitors].
Zhao HF; Zhang Y; Dang LX; Liang JL; Chen SX; Guo Z; Li YL; Zu RR; Gui XD; Wei YP; Song Y
Zhonghua Yi Xue Za Zhi; 2022 May; 102(20):1523-1529. PubMed ID: 35692068
[No Abstract] [Full Text] [Related]
11. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
Cordo' V; Meijer MT; Hagelaar R; de Goeij-de Haas RR; Poort VM; Henneman AA; Piersma SR; Pham TV; Oshima K; Ferrando AA; Zaman GJR; Jimenez CR; Meijerink JPP
Nat Commun; 2022 Feb; 13(1):1048. PubMed ID: 35217681
[TBL] [Abstract] [Full Text] [Related]
12. Advances in the Treatment of Hairy Cell leukemia Variant.
Tran J; Gaulin C; Tallman MS
Curr Treat Options Oncol; 2022 Jan; 23(1):99-116. PubMed ID: 35178674
[TBL] [Abstract] [Full Text] [Related]
13. Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.
Richter J; John K; Staiger AM; Rosenwald A; Kurz K; Michgehl U; Ott G; Franzenburg S; Kohler C; Finger J; Oschlies I; Paul U; Siebert R; Spang R; Burkhardt B; Klapper W
Br J Haematol; 2022 Feb; 196(3):681-689. PubMed ID: 34617271
[TBL] [Abstract] [Full Text] [Related]
14. Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
Yoshida M; Tomizawa D; Yoshimura S; Osumi T; Nakabayashi K; Ogata-Kawata H; Ishiwata K; Sato-Otsubo A; Kimura Y; Ito S; Matsumoto K; Deguchi T; Kiyokawa N; Yoshioka T; Hata K; Kato M
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1545. PubMed ID: 34472720
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia.
Klairmont MM; Zhou Y; Cheng C; Pui CH; Jeha S; Gruber TA; Liu Y; Inaba H; Choi JK
Mod Pathol; 2021 Nov; 34(11):2050-2054. PubMed ID: 34148065
[TBL] [Abstract] [Full Text] [Related]
16. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid leukemia.
Smith CC; Viny AD; Massi E; Kandoth C; Socci ND; Rapaport F; Najm M; Medina-Martinez JS; Papaemmanuil E; Tarver TC; Hsu HH; Le MH; West B; Bollag G; Taylor BS; Levine RL; Shah NP
Clin Cancer Res; 2021 Jul; 27(14):4003-4011. PubMed ID: 34103301
[TBL] [Abstract] [Full Text] [Related]
17. MicroRNA-497/195 is tumor suppressive and cooperates with CDKN2A/B in pediatric acute lymphoblastic leukemia.
Boldrin E; Gaffo E; Niedermayer A; Boer JM; Zimmermann M; Weichenhan D; Claus R; Münch V; Sun Q; Enzenmüller S; Seyfried F; Demir S; Zinngrebe J; Cario G; Schrappe M; Den Boer ML; Plass C; Debatin KM; Te Kronnie G; Bortoluzzi S; Meyer LH
Blood; 2021 Nov; 138(20):1953-1965. PubMed ID: 34098582
[TBL] [Abstract] [Full Text] [Related]
18. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.
Ueno H; Yoshida K; Shiozawa Y; Nannya Y; Iijima-Yamashita Y; Kiyokawa N; Shiraishi Y; Chiba K; Tanaka H; Isobe T; Seki M; Kimura S; Makishima H; Nakagawa MM; Kakiuchi N; Kataoka K; Yoshizato T; Nishijima D; Deguchi T; Ohki K; Sato A; Takahashi H; Hashii Y; Tokimasa S; Hara J; Kosaka Y; Kato K; Inukai T; Takita J; Imamura T; Miyano S; Manabe A; Horibe K; Ogawa S; Sanada M
Blood Adv; 2020 Oct; 4(20):5165-5173. PubMed ID: 33095873
[TBL] [Abstract] [Full Text] [Related]
19. Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.
Defrancesco I; Zibellini S; Boveri E; Frigeni M; Ferretti VV; Rizzo E; Bonometti A; Capuano F; Candido C; Rattotti S; Tenore A; Picone C; Flospergher E; Zerbi C; Bergamini F; Fabbri N; Cristinelli C; Varettoni M; Paulli M; Arcaini L
Hematol Oncol; 2020 Dec; 38(5):689-697. PubMed ID: 32738175
[TBL] [Abstract] [Full Text] [Related]
20. [Efficacy of nilotinib in the first-line treatment of chronic myeloid leukemia and the analysis of factors affecting molecular responses].
Chen LY; Li Z; Zhang Y; Zhou J; Zhao HF; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):477-482. PubMed ID: 32654460
[No Abstract] [Full Text] [Related]
[Next]
